Fig. 1

MAZ is upregulated in PCa tissues with bone metastasis and further elevated in metastatic bone tissues. a MAZ expression level in metastatic bone tissues derived from PCa was robustly elevated compared with that in primary prostate and other common metastatic sites such as liver, lung, through analyzing the publicly available mRNA sequencing dataset of PCa from GSE74685. *P < 0.05. b Real-time PCR analysis of MAZ expression in 89 fresh PCa tissues, including PCa tissues with bone metastases (PCa/BM) and PCa tissues without bone metastases (PCa/nBM), and 15 fresh metastasis bone tissues of PCa (Bone). The case of the lowest normalized CT value of MAZ mRNA was used as a reference whose value defined as 1. The value of all other cases was a multiple of this minimum case. Transcript levels were normalized to GAPDH expression. Lines represent the median and lower/upper quartiles. *P < 0.05. c Western blotting analysis of MAZ expression in 3 PCa/nBM, 3 PCa/nBM and 3 bone tissues respectively. We sequentially numbered each group of cases, and then randomly selected 3 cases in each group. α-tubulin served as the loading control. d Immunohistochemical (IHC) staining of MAZ protein expression in representative samples of PCa/nBM, PCa/BM and bone were shown. e The real-time PCR analysis of MAZ expression levels in the normal prostate epithelial cell (RWPE-1), the non-metastatic PCa cell line 22RV1, bone metastatic PCa cell lines (PC-3, C4-2B, and VCaP) and brain metastatic cell line DU145 and lymph node metastatic cell line LNCaP. Error bars represent the mean ±sd of three independent experiments. *P < 0.05. (F) Western blotting analysis of MAZ expression in PCa cells